Jorma Paavonen focuses on Gynecology, Internal medicine, Chlamydia trachomatis, Cervical cancer and Cervical intraepithelial neoplasia. His biological study spans a wide range of topics, including Cancer, Clinical trial, Vaginal intraepithelial neoplasia, Obstetrics and Risk factor. His research integrates issues of Surgery, Sexually transmitted disease, Immunology and Vaccine efficacy in his study of Internal medicine.
His studies deal with areas such as Chlamydia, Cervicitis, Cervix, Pelvic inflammatory disease and Salpingitis as well as Chlamydia trachomatis. His study looks at the intersection of Cervical cancer and topics like Serology with Gold standard, Chlamydiae and CHLAMYDIAL INFECTIONS. His work deals with themes such as Genital warts, Cumulative incidence, Oncology and Vaccination, which intersect with Cervical intraepithelial neoplasia.
Gynecology, Chlamydia trachomatis, Obstetrics, Internal medicine and Immunology are his primary areas of study. His Gynecology study which covers Cervix that intersects with Cervicitis. His Chlamydia trachomatis research incorporates elements of Chlamydia, Tubal factor infertility and Pelvic inflammatory disease.
His Obstetrics study also includes
Jorma Paavonen mainly investigates Obstetrics, Gynecology, Chlamydia trachomatis, Internal medicine and Vaccination. His Obstetrics study combines topics from a wide range of disciplines, such as Odds ratio, Cohort, Retrospective cohort study, Placental abruption and Amniotic fluid. His Gynecology research also works with subjects such as
His Chlamydia trachomatis study incorporates themes from Tubal factor infertility and Antibody. Internal medicine is closely attributed to Oncology in his work. His Vaccination research is multidisciplinary, incorporating perspectives in Young adult, Randomized controlled trial, Cervical intraepithelial neoplasia and Hepatitis.
Jorma Paavonen focuses on Vaccination, Internal medicine, Gynecology, Randomized controlled trial and Young adult. His studies in Vaccination integrate themes in fields like Cervical cancer, Cervical intraepithelial neoplasia, HPV infection and Clinical trial. Particularly relevant to HPV vaccines is his body of work in Cervical cancer.
His Internal medicine research integrates issues from Surgery, Oncology and Vaccine efficacy. The Gynecology study combines topics in areas such as Miscarriage, Vaginal intraepithelial neoplasia, Colposcopy, Cancer registry and Obstetrics. His Young adult research includes themes of Papillomaviridae and Incidence.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
Luisa L. Villa;Gonzalo Perez;Susanne K. Kjaer;Jorma Paavonen.
The New England Journal of Medicine (2007)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
J. Paavonen;P. Naud;J. Salmeron;C. M. Wheeler.
The Lancet (2009)
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
Jorma Paavonen;David Jenkins;F. Xavier Bosch;Paulo Naud.
The Lancet (2007)
A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection.
LA Koutsky;KK Holmes;CW Critchlow;CE Stevens.
The New England Journal of Medicine (1992)
Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes
Lawrence Corey;Anna Wald;Raj Patel;Stephen L. Sacks.
The New England Journal of Medicine (2004)
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Matti Lehtinen;Jorma Paavonen;Cosette M. Wheeler;Unnop Jaisamrarn.
Lancet Oncology (2012)
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials
Elmar A Joura;Sepp Leodolter;Mauricio Hernandez-Avila;Cosette M Wheeler.
The Lancet (2007)
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up
L. L. Villa;R. L. R. Costa;C. A. Petta;R. P. Andrade.
British Journal of Cancer (2006)
Chlamydia trachomatis: impact on human reproduction
J Paavonen;W Eggert-Kruse.
Human Reproduction Update (1999)
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma.
Tarja Anttila;Pekka Saikku;Pentti Koskela;Aini Bloigu.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: